- Home
- IBRX vs COCO Comparison
IBRX vs COCO Comparison
Compare IBRX & COCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- COCO
- Stock Information
- Founded
- IBRX 2014
- COCO 2004
- Country
- IBRX United States
- COCO United States
- Employees
- IBRX N/A
- COCO N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- COCO Beverages (Production/Distribution)
- Sector
- IBRX Health Care
- COCO Consumer Staples
- Exchange
- IBRX Nasdaq
- COCO Nasdaq
- Market Cap
- IBRX 2.3B
- COCO 1.8B
- IPO Year
- IBRX N/A
- COCO 2021
- Fundamental
- Price
- IBRX $2.44
- COCO $32.44
- Analyst Decision
- IBRX Strong Buy
- COCO Buy
- Analyst Count
- IBRX 5
- COCO 7
- Target Price
- IBRX $11.40
- COCO $37.86
- AVG Volume (30 Days)
- IBRX 7.6M
- COCO 784.4K
- Earning Date
- IBRX 08-05-2025
- COCO 07-30-2025
- Dividend Yield
- IBRX N/A
- COCO N/A
- EPS Growth
- IBRX N/A
- COCO 14.02
- EPS
- IBRX N/A
- COCO 1.07
- Revenue
- IBRX $56,600,000.00
- COCO $559,879,000.00
- Revenue This Year
- IBRX $567.98
- COCO $13.79
- Revenue Next Year
- IBRX $160.56
- COCO $11.16
- P/E Ratio
- IBRX N/A
- COCO $30.27
- Revenue Growth
- IBRX 4227.22
- COCO 11.97
- 52 Week Low
- IBRX $1.83
- COCO $24.09
- 52 Week High
- IBRX $7.48
- COCO $40.32
- Technical
- Relative Strength Index (RSI)
- IBRX 40.38
- COCO 28.63
- Support Level
- IBRX $2.33
- COCO $31.79
- Resistance Level
- IBRX $2.46
- COCO $38.09
- Average True Range (ATR)
- IBRX 0.15
- COCO 1.33
- MACD
- IBRX -0.03
- COCO -0.67
- Stochastic Oscillator
- IBRX 14.10
- COCO 8.27
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About COCO The Vita Coco Company Inc.
The Vita Coco Co Inc is a plant-based functional hydration platform. Its products include Vita Coco Coconut Water, Private Label including coconut water and oil, and Other including Runa, Ever & Ever, and PWR LIFT product offerings, Vita Coco product extensions beyond coconut water, such as Vita Coco Sparkling, coconut milk products, and others. The company has two segments: The Americas segment which comprises of operations in the U.S. and Canada; and The International segment that comprises of operations in Europe, the Middle East, Africa and the Asia Pacific regions. The Americas segment derives maximum revenue. Geographical presence of the company is in United States, United Kingdom and All other countries.